Optimization of Individualized Therapy for CRCs With Secondary RESISTance Towards Anti-EGFR Targeted Therapy Using an Avatar Model
Conditions
- Colo-rectal Cancer
- RAS Wild-type
- UICC III
- UICC II + RF
- UICC IV Curative Intent
Interventions
- DRUG: targeted substance according to the avatar model
Sponsor
PD Dr. med. Volker Heinemann
Collaborators